AOL

Targeted therapy may help treat moderate to severe ulcerative colitis: trial

Ulcerative colitis is a chronic condition characterized by inflammation and ulcers in the colon. Research is ongoing to expand treatment options. A study published in the New England Journal of ...
MyHorryNews

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at ...
MPR

Vedolizumab Promising for Pediatric Ulcerative Colitis After SOC Failure

Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.
newscase

Johnson & Johnson’s Ulcerative Colitis Treatment Demonstrates Sustained Efficacy in Long-Term Study

New 140-week data for J&J's TREMFYA shows 80.8% clinical remission in ulcerative colitis, with 87.5% of early responders ...

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for ...
clinicaladvisor.com

American Gastroenterological Association Releases First “Living” Guideline for Moderate-to-Severe Ulcerative Colitis

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
MedPage Today

Intestinal Ultrasound Is Accurate to Determine Endoscopic Response and Remission in Patients With Moderate to Severe Ulcerative Colitis

Floris de Voogd, MD; Elsa A. van Wassenaer, MD; Aart Mookhoek, MD, PhD; Steven Bots, MD; Sara van Gennep, MD; Mark Löwenberg, MD, PhD; Geert R. D’Haens, MD, PhD ...
Monthly Prescribing Reference

Tremfya Approved for Moderately to Severely Active Ulcerative Colitis

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...
Morningstar

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...